You just read:

U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia

News provided by

Astellas Pharma Inc.

Jul 20, 2017, 08:00 ET